# Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

> **NCT02010242** · PHASE2 · COMPLETED · sponsor: **Calliditas Therapeutics AB** · enrollment: 136 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus With Diabetic Nephropathy

## Interventions

- **DRUG:** GKT137831
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02010242
- **Lead sponsor:** Calliditas Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-02
- **Final completion:** 2015-03
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02010242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02010242, "Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02010242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*